Updates are available Correction dated 2022-07-15
Click to view Correction: https://doi.org/10.1186/s13058-022-01539-7
-
Authors
van Geelen, Courtney T.
Savas, Peter
Teo, Zhi Ling
Luen, Stephen J.
Weng, Chen-Fang
Ko, Yi-An
Kuykhoven, Keilly S.
Caramia, Franco
Salgado, Roberto
Francis, Prudence A.
Dawson, Sarah-Jane
Fox, Stephen B.
Fellowes, Andrew
Loi, Sherene https://orcid.org/0000-0001-6137-9171
- License Information
-
More Information
Article History
Received: 11 May 2020
Accepted: 10 August 2020
First Online: 18 August 2020
Change Date: 15 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13058-022-01539-7
Ethics approval and consent to participate
: Ethics approval for this study was granted by the Peter MacCallum Cancer Centre ethics board (#13/123).
: Not applicable.
: PS acts as a consultant (not compensated) for Roche-Genentech.SL receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis and G1 Therapeutics.PF has received travel and honoraria for lectures from Novartis and AstraZeneca.SJD has received research funding to her institution from Roche-Genentech and Cancer Therapeutics CRC.
